Your browser doesn't support javascript.
loading
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
Lynch, Ryan C; Cassaday, Ryan D; Smith, Stephen D; Fromm, Jonathan R; Cowan, Andrew J; Warren, Edus H; Shadman, Mazyar S; Shustov, Andrei; Till, Brian G; Ujjani, Chaitra S; Libby, Edward N; Philip, Mary; Coye, Hilary; Martino, Christen N; Bhark, Sandra L; Morris, Karolyn; Rasmussen, Heather; Behnia, Sanaz; Voutsinas, Jenna; Gopal, Ajay K.
Afiliación
  • Lynch RC; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Cassaday RD; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Smith SD; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Fromm JR; Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.
  • Cowan AJ; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Warren EH; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Shadman MS; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Shustov A; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Till BG; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Ujjani CS; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Libby EN; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Philip M; Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Coye H; Seattle Cancer Care Alliance, Seattle, WA, USA.
  • Martino CN; Seattle Cancer Care Alliance, Seattle, WA, USA.
  • Bhark SL; Seattle Cancer Care Alliance, Seattle, WA, USA.
  • Morris K; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.
  • Rasmussen H; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.
  • Behnia S; Department of Radiology, University of Washington, Seattle, WA, USA.
  • Voutsinas J; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Gopal AK; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: agopal@uw.edu.
Lancet Haematol ; 8(8): e562-e571, 2021 Aug.
Article en En | MEDLINE | ID: mdl-34329577
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Terapia Recuperativa / Resistencia a Antineoplásicos / Recurrencia Local de Neoplasia Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Lancet Haematol Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Terapia Recuperativa / Resistencia a Antineoplásicos / Recurrencia Local de Neoplasia Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Lancet Haematol Año: 2021 Tipo del documento: Article